Harrow Cuts Earnings Outlook As Costs Climb — Its Sales Target Still Requires A Sprint
Sales rose 39%, but meeting the annual revenue forecast requires roughly 37% to 52% growth in the fourth quarter.
Harrow, which sells eye medicines, cut its 2026 adjusted earnings outlook Monday to more than $40 million from $80 million to $100 million, despite third-quarter sales growth of 39% to $99.3 million. Its earnings release, furnished with an SEC filing, blamed the first-half shortfall and added drug-development and TYRVAYA integration spending.
A Steeper Year-End Sales Climb
Harrow kept its annual revenue target at $350 million to $365 million. That requires approximately $136 million to $151 million in fourth-quarter sales—roughly 37% to 52% above the third quarter, according to its stockholder letter. The comparable increases were 36% in 2024 and 24% in 2025.
Management believes the low end remains achievable, but acknowledged scenarios in which order timing and year-end purchasing leave sales modestly below it. Harrow expects TYRVAYA's first revenue contribution, increasing BYOOVIZ orders and further growth from established medicines to support the finish.
Chairman and CEO Mark L. Baum described the reduced adjusted EBITDA target—earnings before interest, taxes, depreciation, amortization and specified adjustments—as a minimum: “To be clear: our amended Adjusted EBITDA outlook is a floor, and we believe there is opportunity to exceed it.” He expects more than $33 million in fourth-quarter adjusted EBITDA.
VEVYE Grows, Spending Outruns Profit
Branded medicines generated $83.5 million, up 62% year over year, while total revenue increased 41% from the second quarter. Yet quarterly adjusted EBITDA fell to $21.2 million from $22.8 million a year earlier.
Net income increased to $9.8 million from $1.0 million, including a $5.0 million settlement gain involving Ocular Science and OSRX. Commercial and administrative spending reached $53.1 million versus $35.9 million, while research spending rose to $10.3 million from $3.3 million. Operations consumed $27.363 million in cash over the first nine months, compared with generating $35.453 million a year earlier.
VEVYE, Harrow's dry-eye medicine, brought in $39.7 million, up 75% annually. Prescriptions increased approximately 83% year over year and 17% from the second quarter. Earlier insurance-payment assumptions had proved too optimistic: first-half sales were $114.9 million against an expected $133 million to $153 million. Harrow changed its prescription-payment rules in early September to favor insured fills over cash-pay prescriptions.
IHEEZO, an eye anesthetic, produced $25.3 million, up 15% annually. Demand of 62,210 units increased approximately 21% year over year but fell approximately 5% from the second quarter; management cited seasonality and earlier practice stocking. Revenue records shipments to distributors, whereas demand measures practice orders or shipments, rather than necessarily use.
TRIESENCE, a steroid injection, recorded its highest quarterly sales under Harrow ownership at $10.7 million. Demand reached 20,022 units, approximately 110% above a year earlier and 37% above the second quarter. Harrow also prepares customized eye medicines through ImprimisRx; compounding revenue declined to $15.8 million from $20.1 million.
Development Adds Costs And Clinical Risk
Harrow completed its TYRVAYA purchase from Viatris, adding a nasal-spray dry-eye treatment. Transition work and accounting for purchased inventory are expected to reduce fourth-quarter profitability. Harrow also expects higher royalty tiers on certain products.
The company expects to submit its G-MELT FDA approval application before year-end, advancing its previous first-half 2027 plan and bringing application fees and related costs into this year.
Meanwhile, the randomized IHEEZO study of 231 patients failed its main goal of establishing comparable anesthesia effectiveness against proparacaine drops plus a lidocaine injection. Successful anesthesia rates were 55.2% with IHEEZO and 59.7% with the comparator. Exploratory findings favored IHEEZO on post-procedure pain and adverse events, with adverse-event rates of 27% versus 47%; neither group reported serious adverse events. Harrow expects to present full results at the Hawaiian Eye & Retina Conference in January 2027.
Expanded VEVYE coverage through a national plan serving more than 10 million commercially insured people is expected in January 2027. Until then, Harrow's retained sales target depends on a fourth-quarter increase larger than either of its last two year-end climbs.
Sources
- 8-K Filing — HARROW, INC. (HROW) — SEC EDGAR
- Exhibit hrow-20261109xpressrelease.htm — HARROW, INC. 8-K exhibit — SEC EDGAR
- Exhibit hrow-20261109xlettertoshar.htm — HARROW, INC. 8-K exhibit — SEC EDGAR
- Exhibit hrow-20261109xpresentati.htm — HARROW, INC. 8-K exhibit — SEC EDGAR
- Harrow Announces Third Quarter 2026 Financial Results — globenewswire.com
- 8-K filed 2026-10-05 — HARROW, INC. (earlier disclosure) — SEC EDGAR